De Astral Life Support Ventilator van ResMed heeft nu AutoEPAP in de V.S.
SAN DIEGO–(BUSINESS WIRE)–
Andere upgrades zijn eenvoudig wisselen van interface en programmanaamgeving om het gebruiksgemak te verbeteren
ResMed (NYSE: RMD) (ASX: RMD), een wereldleider in de cloud-aangesloten ademhalingsapparatuur, kondigde vandaag belangrijke upgrades aan voor zijn Astral life support ventilatoren, waaronder optionele AutoEPAP in iVAPS voor Amerikaanse patiënten, een optie van high-demand therapie.
Dit persbericht bevat multimedia. Bekijk de volledige weergave hier: https://www.businesswire.com/news/home/20180827005110/en/
Wat is AutoEPAP?
AutoEPAP (automatic expiratory positive airway pressure) past automatisch de uitademdruk van de patiënt aan als reactie op stromingsbeperkingen of obstructie van de bovenste luchtweg.
AutoEPAP is nu beschikbaar in de Verenigde Staten en wordt ook al gebruikt op andere markten. Het is een optie in de iVAPS (intelligent Volume-Assured Pressure Support)-modus van Astral die zich automatisch aanpast aan de veranderende drukbehoeften van een patiënt naarmate zijn ademhalingsaandoening vordert.
ResMed’s Astral Life Support Ventilator Now Has AutoEPAP in U.S.
SAN DIEGO–(BUSINESS WIRE)–
Other upgrades include easy interface switching and program naming to improve ease of use
ResMed (NYSE: RMD) (ASX: RMD), a global leader in cloud-connected respiratory care devices, today announced key upgrades to its Astral life support ventilators, including Optional AutoEPAP in iVAPS for U.S. patients, a high-demand therapy option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180827005110/en/
ResMed’s Astral ventilator (Photo: Business Wire)
What is AutoEPAP?
AutoEPAP (automatic expiratory positive airway pressure) automatically adjusts a patient’s expiratory pressure in response to flow limitations or obstruction of the upper airway.
AutoEPAP is now available in the United States, and already in use in other markets. It’s an option when in Astral’s iVAPS (intelligent Volume-Assured Pressure Support) mode that automatically adapts to a patient’s changing pressure needs as their respiratory disease progresses.
Other upgrades
In addition to AutoEPAP, Astral users worldwide can now:
- Easily change interfaces: Patients can easily change between a mouthpiece and a full face, nasal or pillows mask from a single limb circuit.
- Customize program names: Clinicians can now name programs on a patient’s Astral device for fast, easy access.
“These significant upgrades make Astral one of the most advanced life support ventilators on the market,” said Richie McHale, president of ResMed’s Respiratory Care business. “It’s already proven to stabilize ventilation in significantly fewer breaths than its leading competitor,1 and today’s innovations offer greater ease of use and even more peace of mind to patients across a wide range of respiratory diseases than ever before.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health company with more than 5 million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions. Its 6,000-member team strives to improve patients’ quality of life, reduce the impact of chronic disease and save healthcare costs in more than 120 countries. ResMed.com
1 Diesem Ryan. Astral/Trilogy iVAPS/AVAPS Comparison. Valley Inspired Products 2016; 16011.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180827005110/en/
Contacts
ResMed
For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com
or
For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com